Press Release

6 September 2021 - SYNIMMUNE GmbH is delighted to announce the signing of a manufacturing service agreement with GenScript ProBio, a highly professional and competent CDMO. link

Press Release

10 December 2019 - SYNIMMUNE GmbH Reports Interim Results of First-in-Human Study of Fc-Optimized Antibody FLYSYN for the Treatment of Acute Myeloid Leukemia.

DOWNLOAD

Press Release

30 May 2017 - SYNIMMUNE GmbH Initiates First-in-Human Study of Fc-optimized Antibody FLYSYN for the Treatment of Acute Myeloma.

DOWNLOAD

Closing of Second Financing

23. October 2015 – SYNIMMUNE GmbH has closed a second financing round with its existing investors German Kreditanstalt für Wiederaufbau (KfW) and Synimmune Equity Ltd. The Company will establish an Advisory Board, which will be comprised of Michael Kring, CEO of High Tech Corporate Services, as Chairman, and of Prof. Hans-Georg Rammensee, Founder of SYNIMMUNE GmbH and Head of the Department of Immunology at the University of Tuebingen and a representative of Synimmune Equity. Dr. Martin Steiner, independent consultant for biotechnology companies and former founder and CEO of two biotechnology companies will join SYNIMMUNE as General Manager and CEO.

Closing of First Financing

25. January 2012 - SYNIMMUNE GmbH, a spin-off from the Department of Immunology of the University of Tuebingen, has closed its first financing round with German Kreditanstalt für Wiederaufbau (KfW) and Synimmune Equity. In addition, SYNIMMUNE received a grant from the German Ministry of Education and Research (BMBF) within its GO-Bio program. The funds raised should be sufficient to finance GMP manufacturing of SYNIMMUNE’s lead product FLYSYN and its preclinical development as well as to further develop SYNIMMUNE’s technology platform for bispecific antibodies.

Foundation of SYNIMMUNE GmbH

7. July 2010 – SYNIMMUNE GmbH was founded by Dr. Steffen Aulwurm, Dr. Andreas Herrmann, Dr. Ludger Große-Hovest, Prof. Gundram Jung and Prof. Hans-Georg Rammensee. SYNIMMUNE is a spin-off in the course of an ongoing research project at the Department of Immunology at the University of Tuebingen funded by the German Ministry of Education and research (BMBF) within its GO-Bio program. SYNIMMUNE GmbH will focus on the development of innovative and effective anti-tumor antibodies for the treatment of patients suffering from life-threatening diseases and plans to raise funds from private investors and further research grants.